VF
BCTX

Virtu Financial’s Briacell Therapeutics BCTX Stock Holding History

Virtu Financial’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-324
Closed -$27K – 1369
2024
Q4 		$27K Buy
+324
New +$38.8K ﹤0.01% 1251
2023
Q1 		– Sell
-135
Closed -$89K – 1538
2022
Q4 		$89K Sell
135
-187
-58% -$158K 0.01% 988
2022
Q3 		$272K Buy
322
+252
+360% +$253K 0.02% 701
2022
Q2 		$60K Buy
+70
New +$69.2K 0.01% 1070
2022
Q1 		– Sell
-167
Closed -$207K – 1498
2021
Q4 		$207K Sell
167
-53
-24% -$69.4K 0.02% 821
2021
Q3 		$267K Buy
+220
New +$202K 0.02% 775
2021
Q2 		– Sell
-101
Closed -$58K – 1519
2021
Q1 		$58K Buy
+101
New +$54.9K ﹤0.01% 1415

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Virtu Financial's BCTX Position: Q1 2025 in Review

Virtu Financial sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 324 shares — an estimated $27K sold.

Virtu Financial first reported a position in BCTX in Q1 2021 and held it in 7 quarters. The position peaked at $272K in Q3 2022. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Virtu Financial reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 324 Briacell Therapeutics shares in Q1 2025, an estimated $27K.
  • Virtu Financial first reported a position in Briacell Therapeutics in Q1 2021 and held it in 7 quarters.
  • Virtu Financial's Briacell Therapeutics position peaked at $272K in Q3 2022.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.